CCLG-ALL-2008方案对儿童急性淋巴细胞白血病的疗效及对热休克蛋白90表达的影响  

Efficacy of CCLG-ALL-2008 Regimen in the Treatment of Childhood Acute Lymphoblastic Leukemia and its Influence on the Expression of Heat Shock Protein 90

作　　者：周令 李战华 李运玲 徐学聚[2] 张园[2] ZHOU Ling;LI Zhanhua;LI Yunling(Zhumadian Central Hospital,Zhumadian,463000)

机构地区：[1]河南省驻马店市中心医院,463000 [2]郑州大学第一附属医院,450000

出　　处：《实用癌症杂志》2022年第7期1189-1191,共3页The Practical Journal of Cancer

基　　金：河南省医学科技攻关计划省部共建重点项目(编号:SBGJ202002114)。

摘　　要：目的探讨CCLG-ALL-2008方案对儿童急性淋巴细胞白血病(ALL)的疗效及对热休克蛋白90(Hsp90)表达的影响。方法回顾性分析82例ALL患儿临床资料,依据化疗方法的不同将其分为两组,将接受CCLG-ALL-2008方案治疗的41例患儿纳入观察组,将接受常规多药联合化疗治疗的41例患儿纳入对照组。比较两组临床疗效、Hsp90表达、不良反应、总体生存率(OS)及无事件生存率(EFS)。结果观察组治疗总有效率(RR)高于对照组,Hsp90 mRNA与Hsp90蛋白表达水平低于对照组,OS与EFS高于对照组,差异有统计学意义(P<0.05);两组不良反应总发生率对比,差异无统计学意义(P>0.05)。结论在ALL患儿中采用CCLG-ALL-2008方案治疗有利于抑制Hsp90的表达,提高患儿OS与EFS,且并未增加不良反应,临床应用安全可靠。Objective To investigate the efficacy of CCLG-ALL-2008 regimen in the treatment of childhood acute lymphoblastic leukemia(ALL)and its effect on the expression of heat shock protein 90(HSP90).Methods The clinical data of 82 children with ALL were retrospectively analyzed.They were divided into 2 groups according to different chemotherapy methods,41 children who received CCLG-ALL-2008 regimen were included in the observation group,and 41 children who received conventional multi-drug combined chemotherapy were included in the control group.Clinical efficacy,Hsp90 expression,adverse reactions,overall survival(OS)and event-free survival(EFS)were compared between the 2 groups.Results The total effective rate(RR)of the observation group was higher than that of the control group,the expression of Hsp90 mRNA and Hsp90 protein were lower than those of the control group,OS and EFS were higher than those of the control group,the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the 2 groups(P>0.05).Conclusion CCLG-ALL-2008 regimen is beneficial to inhibit the expression of Hsp90 in children with ALL,improve OS and EFS,and does not increase adverse reactions.It is safe and reliable for clinical application.

关 键 词：急性淋巴细胞白血病 CCLG-ALL-2008方案 热休克蛋白90 生存率 

分 类 号：R733.71[医药卫生—肿瘤]